BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19774358)

  • 1. Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.
    Nagel JM; Mansmann U; Wegscheider K; Röhmel J
    Diabetologia; 2010 Jan; 53(1):206-8. PubMed ID: 19774358
    [No Abstract]   [Full Text] [Related]  

  • 2. [Increased risk of cancer using insulin and insulin analogues?].
    Schäffler A
    MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.
    Simon D
    Diabetologia; 2010 Jan; 53(1):204-5. PubMed ID: 19859691
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin glargine and incidence of cancer--an ongoing debate.
    Hermanns N; Kulzer B
    J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
    Butler PC
    Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitogenic action of insulin: friend, foe or 'frenemy'?
    Draznin B
    Diabetologia; 2010 Feb; 53(2):229-33. PubMed ID: 19851749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
    Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
    Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
    Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
    Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine and cancer--an unsubstantiated allegation.
    Garg SK; Hirsch IB; Skyler JS
    Diabetes Technol Ther; 2009 Aug; 11(8):473-6. PubMed ID: 19591544
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin glargine and the risk of cancer.
    Ahmed FA
    Cardiovasc J Afr; 2010; 21(1):49. PubMed ID: 20224847
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin glargine and malignancy: an unwarranted alarm.
    Pocock SJ; Smeeth L
    Lancet; 2009 Aug; 374(9689):511-3. PubMed ID: 19616841
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
    Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
    Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible link between insulin glargine and malignancy: the facts.
    Mollentze WF
    Cardiovasc J Afr; 2009; 20(4):216-8; discussion 218-9. PubMed ID: 19701528
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of cancer in patients receiving insulin glargine.
    Dawson LK; Hamilton LA
    Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic retinopathy and insulin glargine.
    Chantelau E
    Diabetologia; 2009 Oct; 52(10):2233; author reply 2236-9. PubMed ID: 19680626
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: glargine, a new long-acting insulin analog for diabetic cats.
    Rand J
    J Vet Intern Med; 2006; 20(2):219-20. PubMed ID: 16594574
    [No Abstract]   [Full Text] [Related]  

  • 17. Dualities of interest are not restricted to financial ties to the pharmaceutical industry.
    Nauck M
    Diabetologia; 2010 Jan; 53(1):212-3. PubMed ID: 19921143
    [No Abstract]   [Full Text] [Related]  

  • 18. Insufficient evaluation of adverse events is not a proof of safety.
    Hemkens LG; Grouven U; Bender R; Sawicki PT
    Diabetologia; 2010 Apr; 53(4):790-2; author reply 793-4. PubMed ID: 20099058
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin glargine and cancer: another side to the story?
    Gale EA
    Lancet; 2009 Aug; 374(9689):521. PubMed ID: 19683632
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.